BioSpace News Archive

PTC Therapeutics, Inc. announced that the sole underwriter of its previously announced public offering of 6,720,000 shares of its common stock, which closed on January 25, 2019, has partially exercised its option to purchase additional shares of common stock at the public offering price less underwriting discounts and commissions.

Nektar Therapeutics announced that it will webcast an analyst and investor conference call with lead investigator of the REVEAL study, Dr. Adi Diab, and company management on Friday, March 1, 2019 at 3:00 p.m. Pacific Time during the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium.

In the face of overwhelming need, food banks accelerate progress in closing the hunger gap

CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today reviewed recent progress in the clinical development programs for CTX001, an investigational, autologous, CRISPR/Cas9 gene-edited hematopoietic stem cell therapy being evaluated for patients suffering from severe hemoglobinopathies.

Pharmaceutical Care Management Association President and CEO JC Scott released the following statement on the Senate Finance Committee hearing, “Drug Pricing in America: A Prescription for Change, Part II:"

Praluent® (alirocumab) continues to be available in the U.S.

Hummingbird Bioscience announced today it has been awarded a product development grant totalling $13.1 million from the Cancer Prevention and Research Institute of Texas (CPRIT).

Data recently published in Clinical Cancer Research demonstrate the advantages of using an ultra-high sensitivity test for detection of mutations which may predict therapeutic efficacy for hepatocellular carcinoma (HCC).

Almac Sciences, a member of the Almac Group, has announced a collaboration with Science Exchange, the world’s leading R&D Services Management company.

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Liberty Health Sciences Inc.